These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 9372886

  • 21. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.
    Papatheofanis FJ.
    J Nucl Med; 1997 Aug; 38(8):1175-9. PubMed ID: 9255144
    [Abstract] [Full Text] [Related]

  • 22. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
    Storto G, Klain M, Paone G, Liuzzi R, Molino L, Marinelli A, Soricelli A, Pace L, Salvatore M.
    Bone; 2006 Jul; 39(1):35-41. PubMed ID: 16434248
    [Abstract] [Full Text] [Related]

  • 23. Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton.
    Soerdjbalie-Maikoe V, Pelger RC, Lycklama à Nijeholt GA, Arndt JW, Zwinderman AH, Papapoulos SE, Hamdy NA.
    Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):494-8. PubMed ID: 11914887
    [Abstract] [Full Text] [Related]

  • 24. 89Strontium in the management of painful sceletal metastases.
    Kälkner KM, Westlin JE, Strang P.
    Anticancer Res; 2000 Apr; 20(2B):1109-14. PubMed ID: 10810404
    [Abstract] [Full Text] [Related]

  • 25. Platinum compounds as radiosensitizers in strontium-89 metabolic radiotherapy.
    Sciuto R, Festa A, Tofani A, Pasqualoni R, Semprebene A, Cucchi R, Ferraironi A, Rea S, Maini CL.
    Clin Ter; 1998 Apr; 149(921):43-7. PubMed ID: 9621488
    [Abstract] [Full Text] [Related]

  • 26. Systemic radionuclide therapy of bone metastases with strontium-89.
    Porter AT, Davis LP.
    Oncology (Williston Park); 1994 Feb; 8(2):93-6; discussion 96, 99-101. PubMed ID: 8167090
    [Abstract] [Full Text] [Related]

  • 27. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer.
    Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, Kotler JA, Freeman LM, Olivier P, Quadramet 424Sm10/11 Study Group.
    Urology; 2004 May; 63(5):940-5. PubMed ID: 15134985
    [Abstract] [Full Text] [Related]

  • 28. Strontium-89 (Metastron) versus external beam radiotherapy in patients with painful bone metastases secondary to prostatic cancer: preliminary report of a multicenter trial. UK Metastron Investigators Group.
    Bolger JJ, Dearnaley DP, Kirk D, Lewington VJ, Mason MD, Quilty PM, Reed NS, Russell JM, Yardley J.
    Semin Oncol; 1993 Jun; 20(3 Suppl 2):32-3. PubMed ID: 7684863
    [No Abstract] [Full Text] [Related]

  • 29. [Influence of 89Sr on the cell immune function in patients with multiple bone metastases].
    Wu YG, Ma QL, Liu GF.
    Hunan Yi Ke Da Xue Xue Bao; 2002 Jun 28; 27(3):277-8. PubMed ID: 12575316
    [Abstract] [Full Text] [Related]

  • 30. Palliation of bone pain in patients with metastatic cancer using strontium-89 (Metastron).
    Kan MK.
    Cancer Nurs; 1995 Aug 28; 18(4):286-91. PubMed ID: 7545083
    [Abstract] [Full Text] [Related]

  • 31. [Preliminary application of strontium-89 for the treatment of bone metastases from prostate cancer].
    Zhao W, Deng H, Jie P, Qing C, Zhang X.
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2010 Dec 28; 27(6):1251-4. PubMed ID: 21374974
    [Abstract] [Full Text] [Related]

  • 32. Radionuclide therapy for painful bone metastases. An Italian multicentre observational study. Writing Committee of an Ad Hoc Study Group.
    Piffanelli A, Dafermou A, Giganti M, Colamussi P, Pizzocaro C, Bestagno M, Italian Association of Nuclear Medicine (AINM).
    Q J Nucl Med; 2001 Mar 28; 45(1):100-7. PubMed ID: 11456368
    [Abstract] [Full Text] [Related]

  • 33. Disseminated intravascular coagulation in a patient with metastatic prostate cancer: fatal outcome following strontium-89 therapy.
    Leong C, McKenzie MR, Coupland DB, Gascoyne RD.
    J Nucl Med; 1994 Oct 28; 35(10):1662-4. PubMed ID: 7931669
    [Abstract] [Full Text] [Related]

  • 34. [Radioactive substances (32P and 89Sr) in the treatment of pain in bone metastases].
    Flamm J, Burkert S.
    Z Urol Nephrol; 1981 Nov 28; 74(11):801-6. PubMed ID: 6172913
    [Abstract] [Full Text] [Related]

  • 35. [Internal strontium-89 radiotherapy for malignant bony metastasis].
    Lou C, Zhang D, Yu L.
    Zhonghua Zhong Liu Za Zhi; 2001 Nov 28; 23(6):507-9. PubMed ID: 11859724
    [Abstract] [Full Text] [Related]

  • 36. Strontium-89 in the management of metastatic prostate cancer.
    Kirk D.
    Cancer Surv; 1995 Nov 28; 23():211-5. PubMed ID: 7621459
    [Abstract] [Full Text] [Related]

  • 37. Strontium-89 and low-dose infusion cisplatin for patients with hormone refractory prostate carcinoma metastatic to bone: a preliminary report.
    Mertens WC, Porter AT, Reid RH, Powe JE.
    J Nucl Med; 1992 Aug 28; 33(8):1437-43. PubMed ID: 1634933
    [Abstract] [Full Text] [Related]

  • 38. Patient costs associated with external beam radiotherapy treatment for localized prostate cancer: the benefits of hypofractionated over conventionally fractionated radiotherapy.
    Sethukavalan P, Cheung P, Tang CI, Quon H, Morton G, Nam R, Loblaw A.
    Can J Urol; 2012 Apr 28; 19(2):6165-9. PubMed ID: 22512958
    [Abstract] [Full Text] [Related]

  • 39. [Combined treatment for pain from bone metastases in patients with prostate cancer].
    Ren X, Ying J, Yao D, Ye C, Jiang Y.
    Zhonghua Nan Ke Xue; 2004 Mar 28; 10(3):188-90. PubMed ID: 15080063
    [Abstract] [Full Text] [Related]

  • 40. [Effectiveness of repeated systematic radiotherapy for generalized prostate cancer].
    Kiselev EN, Korytova LI, Karelin MI.
    Vopr Onkol; 2005 Mar 28; 51(6):689-91. PubMed ID: 17037036
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.